Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab

Journal of the American Academy of Dermatology

Volumn 54, Issue 5, 2006, Pages 892-895

  Clayton, Timothy H ^a   Ogden, Stephanie ^a   Goodfield, Mark D J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CLOBETASOL PROPIONATE; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; EFALIZUMAB; HYDROXYCHLOROQUINE; ISOTRETINOIN; LEFLUNOMIDE; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; THALIDOMIDE;

ADULT; ARM; ARTICLE; CASE REPORT; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; EVALUATION; FACE; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; LIMB; LIVER DYSFUNCTION; MALAISE; NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; SKIN LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRUNK;

ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; TREATMENT OUTCOME;

EID: 33646104449     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.08.025     Document Type: Article

References (21)

1. Sontheimer R.D., Thomas J.R., and Gilliam J.N. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 115 (1979) 1409-1415
2. David-Bajar K.M. Subacute cutaneous lupus erythematosus. J Invest Dermatol 105 Suppl 1 (1995) 71S-79S
3. Werther W.A., Gonzalez T.N., O'Connor S.J., McCabe S., Chan B., Hotaling T., et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157 (1996) 4986-4995
4. Drake L.A., Dinehart S.M., and Farmer E.R. Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 34 5 Pt 1 (1996) 830-836
5. Feldmann R., Salomon D., and Saurat J.H. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189 (1994) 425-427
6. Kuhn A., Specker C., Ruzicka T., and Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 46 (2002) 600-603
7. Schanz S., Ulmer A., Rassner G., and Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147 (2002) 174-178
8. Newton R.C., Jorizzo J.L., Solomon Jr. A.R., Sanchez R.L., Daniels J.C., Bell J.D., et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 122 (1986) 170-176
9. Ordi-Ros J., Cortes F., Cucurull E., Mauri M., Bujan S., and Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 27 (2000) 1429-1433
10. Dalziel K., Going G., Cartwright P.H., Marks R., Beveridge G.W., and Rowell N.R. Treatment of chronic discoid lupus erythematosus with an oral gold compound (Auranofin). Br J Dermatol 115 (1986) 211-216
11. Arbiser J.L., and Moschella S.L. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 32 2 Pt 1 (1995) 241-247
12. Aringer M., Stummvoll G.H., Steiner G., Koller M., Steiner C.W., Hofler E., et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 40 (2001) 876-881
13. Aringer M., Feierl E., Steiner G., Stummvoll G.H., Hofler E., Steiner C.W., et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 11 (2002) 102-108
14. Abay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J.M., et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24 (1997) 303-308
15. Meijer C., Huysen V., Smeenk R.T., and Swaak A.J. Profiles of cytokines (TNF and IL6) and acute phase proteins (CRP and 1AG) related to disease course in patients with systemic lupus erythematosus. Lupus 2 (1993) 359-365
16. Maury C.P., and Teppo A.M. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 32 (1989) 146-150
17. Gensburger D., Kawashima M., Marotte H., Kanitakis J., and Miossec P. Lupus erythematosus with leflunomide: induction or reactivation?. Ann Rheum Dis 64 (2005) 153-155
18. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50 (2004) 3161-3169
19. Bleumink G.S., ter Borg E.J., Ramselaar C.G., and Ch Stricker B.H. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 40 (2001) 1317-1319
20. Fautrel B., Foltz V., Frances C., Bourgeois P., and Rozenberg S. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent. Arthritis Rheum 46 (2002) 1408-1409
21. Leonardi C.L. Efalizumab in the treatment of psoriasis. Dermatol Ther 17 (2004) 393-400